Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CELU vs ABEO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABEO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 9–1 Matrix Metrics)

ABEO Overall Winner 6-Pillar Tally: CELU 1 – 4 ABEO (1 Tie) Matrix Metrics: CELU 1 – 9 ABEO

As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over Celularity Inc. (CELU) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CELU carries a Unified Composite Score of 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin), whereas ABEO carries 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin).

  • Technical & Structure Timing Caution: CELU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CELU vs ABEO
CELU NASDAQ
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap $15.2M
TTM Revenue $19M
Forward P/E N/M
Beta / 30D Vol 2.01β · 135% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.3%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.71 · SMA50: $1.08
ABEO NASDAQ Head-to-Head Winner
Abeona Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.42
-1.22% 1D
Market Cap $167.4M
TTM Revenue $39M
Forward P/E 18.7x
Beta / 30D Vol 0.60β · 149% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 60.0 Fund 61.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.9%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $3.39 · SMA50: $4.38

6-Pillar Scorecard Institutional Category Breakdown (CELU 1 – 4 ABEO)

Columns: Metric · CELU · ABEO
1. Valuation Multiples ABEO
Forward P/E N/M 18.7x
Trailing P/E N/M 18.7x
PEG Ratio N/M N/M
EV / Revenue 2.7x 3.0x
2. Growth & Scale ABEO
Revenue Growth (YoY) -5.3% +2745.0%
Earnings Growth (YoY) -61.3% +0.0%
TTM Revenue (USD) $19M $39M
Market Cap $15.2M $167.4M
3. Profitability & Quality ABEO
Gross Margin 19.2% -3.5%
Operating Margin -254.0% -186.1%
Net Profit Margin -245.7% -160.3%
Return on Equity (ROE) -6367.2% -42.1%
4. Balance Sheet & Cash Flow CELU
Cash Generation (TTM) -$8.9M -$66M
Cash Flow Margin -47.8% N/A
Net Cash / Leverage $35M Net Debt $50M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABEO
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 116.6% (50th %ile) 165.8% (27th %ile)
Put/Call OI Skew 3.60x (Put-Skewed) 0.26x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CELU (1) vs ABEO (9)
Institutional Metric CELU ABEO Criterion Row Edge
Market Capitalization
Scale
$15.2M $167.4M Larger Scale ABEO
Trailing P/E Ratio
Valuation
N/M 18.7x Lower Multiple ABEO
Forward P/E Ratio
Valuation
N/M 18.7x Lower Multiple ABEO
Revenue Growth (YoY)
Growth
-5.3% +2745.0% Higher Growth ABEO
Operating Margin (TTM)
Profitability
-254.0% -186.1% Higher Margin ABEO
Net Profit Margin
Profitability
-245.7% -160.3% Higher Margin ABEO
Return on Equity (ROE)
Capital Efficiency
-6367.2% -42.1% Higher ROE ABEO
52-Week Range Position
Momentum
2% ($0–$3) 6% ($2–$8) Stronger Trend ABEO
Beta / 30D Volatility
Risk Regime
2.01β · 135% Vol 0.60β · 149% Vol Lower Realized Risk CELU
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 49.9 / 100 (HOLD) Higher Composite ABEO
Trailing 12M Revenue (USD)
Operating Scale
$19M $39M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
19.2% -3.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.7x EV/Rev N/M PEG · 3.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.9M ($35M Net Debt) -$66M ($50M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABEO +10.04 pp
CELU: -55.9% · ABEO: -45.86%
3M Horizon CELU +19.83 pp
CELU: -40.24% · ABEO: -60.07%
6M Horizon CELU +8.72 pp
CELU: -46.79% · ABEO: -55.51%
1Y Horizon ABEO +30.22 pp
CELU: -72.6% · ABEO: -42.38%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CELU Revenue ABEO Revenue CELU Op. Margin ABEO Op. Margin Margin Leader
FY2017 N/A $0M N/A -3325.7% ABEO
FY2018 N/A $0M N/A -1940.2% ABEO
FY2020 $10M $10M -1064.0% -814.2% ABEO
FY2021 $20M $0M -511.2% -2994.5% CELU
FY2022 $20M $0M -142.4% -3600.8% CELU
FY2023 $20M $0M -844.4% -1346.7% CELU
FY2024 $50M N/A -70.7% N/A CELU
FY2025 $30M $10M -230.9% -1536.9% CELU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CELU BREAKDOWN
60d in phase · OBV NEUTRAL
Current IV 116.6%
IV Percentile 50th %ile
Put/Call OI Skew 3.60x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CELU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABEO BREAKDOWN
71d in phase · OBV NEUTRAL
Current IV 165.8%
IV Percentile 27th %ile
Put/Call OI Skew 0.26x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CELU Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.2M market capitalization and -254.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABEO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $167.4M market capitalization and -186.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CELU vs ABEO Key Questions & Quantitative Answers

As of Nov 20, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over Celularity Inc. (CELU) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CELU carries a Unified Composite Score of 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin), whereas ABEO carries 49.9/100 (HOLD) at $2.42 (18.7x Forward P/E, -186.1% operating margin). Technical & Structure Timing Caution: CELU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABEO leads the Growth & Scale pillar: CELU posts -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin), compared with ABEO at +2745.0% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-3.5% gross margin, -186.1% operating margin). Across the 8-period historical trajectory (FY2017 to FY2025), CELU cumulative revenue shifted +200.0% while ABEO shifted +0.0%. In operating R&D and SG&A reinvestment, CELU deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABEO.

ABEO screens cheaper on headline valuation multiples. CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin), whereas ABEO trades at 18.7x Forward P/E, 18.7x Trailing P/E, N/M PEG, and 3.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CELU (-6367.2% ROE) versus ABEO (-42.1% ROE) capital efficiency.

In options market volatility and institutional positioning, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk). By comparison, ABEO carries 165.8% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.60β · 149% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.